The International Symposium on the Frontiers of Precision Medicine and Future Healthcare opened in Shanghai on Wednesday.
The four-day conference will exhibit the study fruits of precision medicine and future healthcare in a range of full aspects. According to the National Health and Family Planning Commission, China is formulating strategic planning for precision medicine, which is expected to become a major scientific and technology specific project of the 13th Five-Year Plan.
A group of A-share listed companies are engaged in precision medicine relevant business. They include Zhongyuan Union Cell & Gene Engineering Co., Ltd. (600645.SH), Boai Nky Pharmaceuticals Ltd. (300109.SZ) and Da An Gene Co., Ltd. (002030.SZ).
Latest comments